Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016781 · ClinicalTrials.gov registry record · Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT02016781 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 384 participants.
The verdict
NCT02016781, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Interventions
- PROCEDURE Allogeneic Hematopoietic Cell Transplant
- PROCEDURE Hypomethylating Therapy / Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2021-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016781
The ClinicalTrials.gov registry entry for NCT02016781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allogeneic Hematopoietic Cell Transplant is the first listed.
NCT02016781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02016781 about?
NCT02016781 is a clinical study titled "Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)". This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
What is the current status of trial NCT02016781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2013-12-16. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT02016781?
The interventions under investigation include: Allogeneic Hematopoietic Cell Transplant (PROCEDURE), Hypomethylating Therapy / Best Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT02016781?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.